Current market catalysts

Oppenheimer Maintains Outperform on Ensign Group, Raises Price Target to $215

Keybanc Maintains Overweight on Alphabet, Lowers Price Target to $385

ATI Q3 2026 Earnings Call Transcript

ATI (NYSE:ATI) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

Oppenheimer Maintains Outperform on ServiceNow, Maintains $165 Price Target

LENZ Therapeutics Q3 2026 Earnings Call Transcript

LENZ Therapeutics (NASDAQ:LENZ) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga

FTAI Aviation Q3 2026 Earnings Call Transcript

FTAI Aviation (NASDAQ:FTAI) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.

Everest Group Q3 2026 Earnings Call Transcript

Everest Group (NYSE:EG) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

8-K filing — Dream Finders Homes, Inc. (DFH)

Filed: 2026-10-29 AccNo: 0001628280-26-068063 Size: 414 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

8-K filing — Celularity Inc (CELU)

Filed: 2026-10-29 AccNo: 0001493152-26-049203 Size: 236 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — ADT Inc. (ADT)

Filed: 2026-10-29 AccNo: 0001193125-26-437123 Size: 192 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Federal Home Loan Bank of Cincinnati

Filed: 2026-10-29 AccNo: 0001326771-26-000173 Size: 522 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

8-K filing — KKR FS Income Trust Select

Filed: 2026-10-29 AccNo: 0001104659-26-119974 Size: 189 KB Item 8.01: Other Events

8-K filing — KKR FS Income Trust

Filed: 2026-10-29 AccNo: 0001104659-26-119971 Size: 189 KB Item 8.01: Other Events

New Strong Sell Stocks for October 29th

Zacks has added three stocks to its Strong Sell list today: Centerra Gold Inc., Gentherm Incorporated, and Grupo Televisa. All three companies have experienced significant downward revisions to their current year earnings estimates over the last 60 days, ranging from 6.2% to 19.6%.

New Strong Buy Stocks for October 29th

Zacks has added five stocks to its Strong Buy list based on positive earnings estimate revisions over the last 60 days. The stocks include Oddity Tech (AI-driven beauty brands), DMC Global (specialty products for energy/industrial markets), Sierra Bancorp (bank holding company), Albany International (engineered materials manufacturer), and Murphy Oil (oil and gas exploration company).

Company News for Oct 29, 2026

Several companies reported third-quarter 2026 earnings with mixed results. Waste Management missed consensus estimates causing a 4.5% share decline, while Ultra Clean Holdings, PPG Industries, and Crane Co. all beat expectations and saw share price increases of 2.9% to 8.6%.

Stock Market News for Oct 29, 2026

U.S. stock markets rose on Wednesday as the Federal Reserve kept interest rates unchanged at 3.75-4% and strong third-quarter earnings boosted investor confidence. The Dow Jones, Nasdaq Composite, and S&P 500 all ended in positive territory. Notable earnings beats from Seagate Technology, Amphenol Corp., and Labcorp Holdings drove their stock prices higher by 4.5%, 3.5%, and 8.8% respectively.

Best Growth Stocks to Buy for October 29th

Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth potential: ATI Inc., a specialty materials company with 7.8% earnings estimate increase; Micron Technology, a memory and storage products seller with 12.6% earnings estimate increase; and Valero Energy, a transportation fuels company with a significant 41.1% earnings estimate increase over the last 60 days.

Prediction: Marvell Stock Will Be Worth This Much by 2030

Marvell Technology is positioned as a major beneficiary of the AI infrastructure boom, particularly through its custom silicon business for hyperscalers. Management targets $30 EPS by 2030, with analysts projecting stock valuations ranging from $234 (pessimistic) to $780 (optimistic) depending on execution. The company's growth is driven by demand for custom AI chips, interconnect technology, and XPU attach products, though risks include customer spending changes and increased competition.

Should You Buy Tesla Stock Right Now? The Answer Might Surprise You.

Tesla's core EV business continues to struggle with declining deliveries and shrinking earnings despite a 20% stock decline from its all-time high. With a P/E ratio of 434—14 times higher than the Nasdaq-100—and future products like Optimus and Cybercab still years away from commercialization, the analyst recommends against buying Tesla stock in the near term, citing downside risk as competition from Chinese manufacturers intensifies.

MISL vs. JETS ETFs: Defense Stability Versus Airline Cyclicality

The First Trust Indxx Aerospace & Defense ETF (MISL) and U.S. Global Jets ETF (JETS) both charge 0.6% expense ratios but differ significantly in risk and returns. MISL focuses on defense contractors with lower volatility (0.91 beta, 18.4% max drawdown), while JETS tracks airlines with higher volatility (1.30 beta, 48.3% max drawdown) but offers better dividend yield (0.9% vs 0.1%). MISL is better suited for risk-averse long-term investors, while JETS appeals to income-focused investors willing to tolerate cyclical airline industry exposure.

The 5 Numbers That Matter Most in a Bank's Earnings Report

Major banks including JPMorgan Chase, Bank of America, and Wells Fargo reported third-quarter earnings that largely disappointed expectations. The article identifies five key metrics investors should focus on when evaluating bank performance: net interest income, provision for credit losses, common equity tier 1, return on tangible common equity, and earnings per share.

Sandisk's Surging Profits Face a Critical Test

Sandisk is attempting to stabilize the volatile NAND memory business through long-term customer agreements worth $91.1 billion. The company's upcoming earnings results will test whether these commitments can deliver sustained profitability, as the stock has experienced significant volatility with a 45% decline from recent highs.

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

Candel Therapeutics announced that its phase 2 PrTK05 clinical trial data for aglatimagene besadenovec in localized prostate cancer has been accepted for poster presentation at the SITC 41st Annual Meeting in November 2026. The presentation will feature longitudinal immune-profiling, biodistribution, and viral shedding data from the trial combining aglatimagene with valacyclovir and radiation therapy.

What a $1,000 Investment in Palantir Could Be Worth by the End of 2027 (The Answer May Surprise You)

Palantir Technologies trades at an expensive 122x forward earnings valuation despite strong revenue growth and impressive 55% profit margins. The analyst argues the stock is overvalued with too much growth already priced in, predicting it will lose value by late 2027 as investors pivot to competing AI companies like Anthropic and OpenAI. The stock would need earnings to triple to justify current valuations at reasonable multiples.

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Immunocore announced it will present Phase 1 data for brenetafusp combined with KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the 2026 SITC Annual Meeting. The presentation will showcase clinical data for the first combination of two T cell engagers in a solid tumor, with poster and oral sessions scheduled for November 6-7, 2026.

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. (Nasdaq: XGN), a specialized autoimmune diagnostics company, announced it will participate in two investor conferences in November 2026 and will release its third quarter financial results on November 10, 2026. The company previously reported strong Q2 2026 results with record revenue, test volume, and trailing twelve-month average selling price, leading to increased full-year revenue guidance.

What Happens to Rocket Lab Stock if Neutron Slips Further?

Rocket Lab reported 62% year-over-year revenue growth and a $2.36 billion backlog, but further delays to its Neutron rocket launch raise concerns about the company's valuation, future profitability, and potential shareholder dilution. The analysis examines how additional delays could impact the stock while noting that the company's growing satellite business remains a positive factor.

NCH Rooney Heart Institute Performs Nation’s First Tricuspid Valve Repair with PASCAL Precision System Following FDA Approval

Naples Comprehensive Health (NCH) has performed the nation's first tricuspid valve repair using Edwards Lifesciences' PASCAL Precision system following FDA approval. The procedure expands minimally invasive treatment options for patients with severe tricuspid regurgitation, building on NCH's role as the highest-enrolling clinical trial site for the therapy.

8-K filing — Catalyst Bancorp, Inc. (CLST)

Filed: 2026-10-29 AccNo: 0001104659-26-119968 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits